453 results on '"Morra, Enrica"'
Search Results
2. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the “Rete Ematologica Lombarda”
3. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
4. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013
5. Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition
6. Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”
7. Should a Positive Direct Antiglobulin Test Be Considered a Prognostic Predictor in Chronic Lymphocytic Leukemia?
8. Microarray Demonstrates Different Gene Expression Profiling Signatures Between Waldenström Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
9. Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia
10. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
11. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
12. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience
13. Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
14. Report From the Sixth International Workshop on Waldenström's Macroglobulinemia
15. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia
16. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
17. Flow cytometry vs cytomorphology for the detection of hematologic malignancy in body cavity fluids
18. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes
19. Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age ≥75 years: A retrospective analysis of the Rete Ematologica Lombarda
20. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma
21. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
22. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia
23. Verifying Hellström-Lindberg score as predictive tool for response to erythropoietin therapy according to the “International Working Group” criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience
24. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups
25. Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study
26. Flow cytometry and cytomorphology evaluation of hematologic malignancy in cerebrospinal fluids: comparison with retrospective clinical outcome
27. A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis
28. Prognostic value of circulating CD34 + cells in myelodysplastic syndromes
29. Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature
30. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study
31. Cryoglobulinemia
32. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
33. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta
34. Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes
35. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
36. Splenic marginal zone lymphoma: a prognostic model for clinical use
37. Fludarabine Plus Cyclophosphamide and Rituximab in Waldenstrom Macroglobulinemia: An Effective but Myelosuppressive Regimen to be Offered to Patients With Advanced Disease
38. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
39. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas
40. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients
41. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
42. Bendamustine: new perspective for an old drug in lymphoproliferative disorders
43. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients
44. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma
45. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura
46. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations : A report of three cases
47. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients
48. Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid
49. Limited Feasibility of Double Transplant in Multiple Myeloma: Results of a multicenter study on 153 patients aged <65 years
50. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.